Factors of treatment response in autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at factors that help predict how well people with autoimmune hepatitis respond to treatment. It is for patients who are newly diagnosed or have not had treatment for at least 3 months, and who have had a liver biopsy to confirm the diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have autoimmune hepatitis diagnosed by a special scoring system (AIH score of 6 or more) and a liver biopsy that confirms it.
- Either you have never been treated for autoimmune hepatitis, or you stopped taking steroids or immune-suppressing medicines at least 3 months ago.
- You do not have other liver diseases like viral hepatitis, drug-induced liver injury, or alcoholic liver disease.
- You have not had a bone marrow or liver transplant, are not pregnant or breastfeeding, and do not have serious mental health conditions or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
This test compares two medicines—azathioprine and mycophenolate mofetil (MMF)—to see which is better at putting autoimmune hepatitis into remission without using steroids first. It is for people who have just been diagnosed and haven't started treatment yet.
This study examines the molecular profile of autoimmune hepatitis (a liver condition where the immune system attacks liver cells) using lipid analysis. Researchers hope to better understand the disease and potentially improve diagnosis and treatment in the future.
This study tests whether a Mediterranean diet can reduce fatigue in people with autoimmune hepatitis (AIH) compared to a typical Western diet. You will receive frozen meals for a week and track your energy levels.
This trial tests a new medication called inebilizumab for people with autoimmune hepatitis (a condition where the body's immune system attacks the liver) who haven't responded well to standard treatments or can't tolerate them. The study aims to see if this new drug can help control liver inflammation and reduce the need for high-dose steroids.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.